SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at the BioCentury NewsMakers
Conference on Thursday, September 6, 2007 at 2:30 p.m. ET in New York, at
the Thomas Weisel Healthcare Conference on Friday, September 7, 2007 at
9:10 a.m. ET in Boston and at the Bear Stearns Healthcare Conference on
Monday, September 10, 2007 at 9:00 a.m. ET in New York. Daniel M. Bradbury,
President and Chief Executive Officer of Amylin Pharmaceuticals, will be
providing a corporate overview at BioCentury NewsMakers and Thomas Weisel.
Mark G. Foletta, Senior Vice President, Finance and Chief Financial Officer
of Amylin Pharmaceuticals, will be providing a corporate overview at Bear
Stearns.
The live presentations and breakout sessions will be webcast, and
recordings will be made available following the events. The webcasts and
recordings will be accessible through Amylin's corporate website, located
at http://www.amylin.com. To access the live webcasts, please log on to
Amylin's site approximately fifteen minutes prior to the presentation to
register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,700 employees nationwide.
Further information on Amylin Pharmaceuticals and its pipeline in
metabolism is available at http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Alice Bahner Izzo, Executive Director,
Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200, ext. 7272
|
